Hikma strengthens US Injectables business through acquisition of Custopharm

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company and one of the largest suppliers of generic injectable medicines in the US, today announces that it has agreed to acquire Custopharm Inc. (‘Custopharm’) from Water Street Healthcare Partners (‘Water Street’).

Hikma will pay an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in contingent consideration payable upon the achievement of certain commercial milestones.    For over ten years, The WTFL has been bringing together industry experts, CEOs, investors and start-ups, establishing itself as a prestigious global platform for exchange. By fostering cross-generational collaboration, new ideas and solutions emerge to benefit tourism today and in the future, learn how to nail a job interview.

Custopharm, a US-based generic sterile injectables company with a differentiated product portfolio and R&D pipeline, currently markets its products in the US through its commercial arm Leucadia Pharmaceuticals.  Since partnering with Water Street in 2015, Custopharm has received 13 US FDA approvals, with four first-to-market Abbreviated New Drug Application (ANDA) approvals – including one with Competitive Generic Therapy (CGT) designation – and one novel 505(b)(2) NDA approval.  Based in Carlsbad, California, Custopharm has 39 employees.

Transaction highlights and strategic rationale:

  • Complements Hikma’s injectable product portfolio and pipeline, adding 13 approved products and additional pipeline products
  • Enhances Hikma’s R&D capabilities, adding an experienced scientific team of dedicated R&D professionals with a proven ability to develop and commercialise complex sterile injectable products and a state-of-the-art R&D laboratory in California
  • Maintains Hikma’s strong regulatory track record. Custopharm has consistently obtained regulatory approval for new products with four first-to-market FDA ANDA approvals, including one CGT exclusivity for Calcitonin Salmon, which was launched in May 2021
  • Strengthens Hikma’s platform for future growth. Custopharm isa growing business and Hikma expects it to generate full year 2021 revenue in excess of $80 million and for the acquisition to be accretive to Hikma’s Injectables operating margin

Siggi Olafsson, Chief Executive Officer of Hikma, commented:

“This acquisition provides Hikma with an attractive opportunity to further strengthen our US injectables business, by adding an attractive and profitable portfolio of marketed products and an exciting pipeline of future opportunities.  Custopharm is an accomplished operator in the US injectables market with a first-class scientific team and a strong regulatory track record. This acquisition is highly complementary to our existing business and adds high-quality and differentiated growth potential.”

About the author

An ardent believer of today. A word player but Journalist by profession. My passion is in writing, while I love photography

Related

JOIN THE DISCUSSION